MPC 3100

Drug Profile

MPC 3100

Alternative Names: MPC-3100

Latest Information Update: 26 Nov 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Myriad Pharmaceuticals
  • Developer Myrexis
  • Class Antineoplastics; Purines; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Cancer

Most Recent Events

  • 09 Nov 2012 The Board of Directors of Myrexis announces a plan of complete liquidation and dissolution of the company
  • 11 May 2012 Myrexis intends to out-license all its preclinical and clinical programmes, including MPC 3100, for further development
  • 28 Mar 2012 Adverse events and pharmacodynamics data from a phase I trial in Cancer presented at the 243rd National Meeting of the American Chemical Society (243rd-ACS-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top